Cerebrolysin is a peptidergic drug produced from purified
porcine brain proteins, with postulated neurotrophic and
neuroprotective effects (Windisch et al., 1998; Rockenstein
et al., 2003; Plosker and Gauthier, 2009; Gauthier et al.,
2015). A small open-label trial in patients with AD and VaD
(Rainer et al., 1997) showed minimal improvement in cognitive
tests and clinical global impression. The main side
effects were nausea and vertigo. A Cochrane review (Chen et al., 2013) of six RCTs with a total of 597 participants
showed minimal MMSE and ADAS-cog improvements.
